Kymera Therapeutics (KYMR) Operating Leases (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Operating Leases for 8 consecutive years, with $65.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 7.86% year-over-year to $65.6 million; the TTM figure through Mar 2026 stood at $65.6 million (down 7.86% YoY), while the FY2025 annual figure was $67.0 million, down 7.44% from the prior year.
• Operating Leases slipped to $65.6 million in Q1 2026 per KYMR's latest filing, from $67.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $77.0 million in Q4 2023 and bottomed at $12.1 million in Q4 2022.
• Historically, Operating Leases has averaged $57.5 million across 5 years, with a median of $69.8 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Leases fell 8.15% — and 2023, when it soared 534.18%.
• Kymera Therapeutics' Operating Leases stood at $12.1 million in 2022, then jumped by 534.18% to $77.0 million in 2023, then dropped by 5.98% to $72.4 million in 2024, then dropped by 7.44% to $67.0 million in 2025, then slipped by 2.16% to $65.6 million in 2026.
• Business Quant data shows KYMR's Operating Leases at $65.6 million in Q1 2026, $67.0 million in Q4 2025, and $68.4 million in Q3 2025.